

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/797,157
Filing Date	03/09/2004
First Named Inventor	Martin OFT
Art Unit	1045 1646
Examiner Name	D. Jiang
Attorney Docket Number	DX06022 US 01

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T ³
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				


NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DJ	AA	Broberg, et al. (2002) <i>J. Interferon Cytokine Res.</i> 22:641-651 "Herpes Simplex Virus Type 1 Infection Induces Upregulation of Interleukin-23 (p19) mRNA Expression in Trigeminal Ganglia of BALB/c Mice"	
DJ	AB	Cannistra and Niloff (1996) <i>New Engl. J. Med.</i> 334:1030-1038 "Cancer of the Uterine Cervix"	
DJ	AC	Cooper, et al. (2002) <i>J. Immunol.</i> 168:1322-1327 "Mice Lacking Bioactive IL-12 Can Generate Protective, Antigen-Specific Cellular Responses to Mycobacterial Infection Only if the IL-12 p40 Subunit Is Present"	

Examiner Signature	/Dong Jiang/	Date Considered	06/14/2006
-----------------------	--------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/797,157
Filing Date	03/09/2004
First Named Inventor	Martin OFT
Art Unit	1045 1646
Examiner Name	D. Jiang
Attorney Docket Number	DX06022 US 01

Sheet 2 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DJ	AD	Cua, et al. (2003) <i>Nature</i> 421:744-748 "Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain"	
	AE	Elkins, et al. (2002) <i>Infection Immunity</i> 70:1936-1948 "In Vivo Clearance of an Intracellular Bacterium, <i>Francisella tularensis</i> LVS, Is Dependent on the p40 Subunit of Interleukin-12 (IL-12) but Not on IL-12 p70"	
	AF	Enzinger and Mayer (2003) <i>New Engl. J. Med.</i> 349:2241-2252 "Esophageal Cancer"	
	AG	Farrar, et al. (1999) <i>J. Immunol.</i> 162:2842-2849 "Cancer Dormancy. VII. A Regulatory Role for CD8 ⁺ T Cells and IFN- γ in Establishing and Maintaining the Tumor-Dormant State"	
	AH	Fischer, et al. (1997) <i>Nature Biotechnol.</i> 15:142-145 "A bioactive designer cytokine for human hematopoietic progenitor cell expansion"	
	AI	Forastiere, et al. (2001) <i>New Engl. J. Med.</i> 345:1890-1900 "Head and Neck Cancer"	
	AJ	Frucht (2002) <i>Sci STKE</i> 2002, E1-E3 "IL-23: A Cytokine That Acts on Memory T Cells"	
	AK	Izbicki, et al. (1997) <i>New Engl. J. Med.</i> 337:1188-1194 "Prognostic Value of Immunohistochemically Identifiable Tumor Cells in Lymph Nodes of Patients with Completely Resected Esophageal Cancer"	
	AL	Le, et al. (2001) <i>J. Immunol.</i> 167:6765-6772 "Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-12"	
	AM	Lynch and Chapelle (2003) <i>New Engl. J. Med.</i> 348:919-932 "Hereditary Colorectal Cancer"	
↓	AN	Oppmann, et al. (2000) <i>Immunity</i> 13:715-725 "Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12"	

Examiner Signature	/Dong Jiang/	Date Considered	06/14/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/797,157
				Filing Date	03/09/2004
				First Named Inventor	Martin OFT
				Art Unit	1645 1646
				Examiner Name	D. Jiang
Sheet	3	of	3	Attorney Docket Number	DX06022 US 01

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
DJ	AO	Osborne (1998) <i>New Engl. J. Med.</i> 339:1609-1618 "Tamoxifen In the Treatment of Breast Cancer"		
	AP	Parham, <i>et al.</i> (2002) <i>J. Immunol.</i> 168:5699-5708 "A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12R β 1 and a Novel Cytokine Receptor Subunit, IL-23R"		
	AQ	Peters, <i>et al.</i> (1998) <i>J. Immunol.</i> 161:3575-3581 "In Vivo and In Vitro Activities of the gp130-Stimulating Designer Cytokine Hyper-IL-6"		
	AR	Pirhonen, <i>et al.</i> (2002) <i>J. Immunol.</i> 169:5673-5678 "Regulation of Virus-Induced IL-12 and IL-23 Expression in Human Macrophages"		
	AS	Rakemann, <i>et al.</i> (1999) <i>J. Biol. Chem.</i> 274:1257-1266 "The Designer Cytokine Hyper-Interleukin-6 Is a Potent Activator of STAT3-dependent Gene Transcription <i>in Vivo</i> and <i>in Vitro</i> "		
	AT	Ramirez-Montagut, <i>et al.</i> (2003) <i>Oncogene</i> 22:3180-3187 "Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity"		
	AU	Sawaya, <i>et al.</i> (2003) <i>New Engl. J. Med.</i> 349:1501-1509 "Risk of Cervical Cancer Associated with Extending the Interval between Cervical-Cancer Screenings"		
	AV	Wiekowski, <i>et al.</i> (2001) <i>J. Immunol.</i> 166:7563-7570 "Ubiquitous Transgenic Expression of the IL-23 Subunit p19 Induces Multiorgan Inflammation, Runting, Infertility, and Premature Death"		

Examiner Signature	/Dong Jiang/	Date Considered	06/14/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/797,157
Filing Date	03/09/2004
First Named Inventor	Martin OFT
Art Unit	1645 1646
Examiner Name	D. Jiang
Attorney Docket Number	DX06022 US 01

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
DJ	AW	WO 01/18051 A2	03-15-2001	Schering Corporation		
DJ	AX	WO 01/85790 A2	11-15-2001	Schering Corporation		
DJ	AY	WO 02/29060 A2	04-11-2002	Immunex Corporation		
DJ	AZ	WO 02/097048 A2	12-05-2002	Centocor, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DJ	BA	UGAI, <i>et al.</i> (2003) <i>Cancer Gene Therapy</i> 10:771-778 "Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects"	
DJ	BB	LO, <i>et al.</i> (2003) <i>J. Immunol.</i> 171:600-607 "Antitumor and Antimetastatic Activity of IL-23"	

Examiner Signature	/Dong Jiang/	Date Considered	06/14/2006
-----------------------	--------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.